brecanavir
Small moleculeexperimental
Brecanavir is a protease inhibitor which has been studied for the treatment of HIV. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2004 (NCT00257621)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- HIV-1 proteaseINHIBITOR
HIV-1 protease inhibitor
HIV-1 protease inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(COc2ccc(C[C@H](NC(=O)O[C@H]3CO[C@H]4OCC[C@H]43)[C@H](O)CN(CC(C)C)S(=O)(=O)c3ccc4c(c3)OCO4)cc2)cs1- Mol. weight
- 703.84 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBrecanavir ↗
- ChEMBLCHEMBL206031 ↗
Also known as
- (1s,2r)-3-((1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino-2-hydroxy-1-((4-(2-methyl-4-thiazolyl)methoxy)phenyl)methylpropyl)carbamic acid, hexahydrofuro(2,3-b)furan-3yl ester
- bcv
- bcv
- brecanavir
- brecanavir
- brecanavir
- brecanavir
- gw640385
- gw640385
- gw640385
- gw64085x
- gw64085x
- vx385
- vx-385
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00242879 | Phase 2 | Aug 1, 2005 | GlaxoSmithKline, ViiV Healthcare |
| NCT00257621 | Phase 2 | Oct 1, 2004 | GlaxoSmithKline, ViiV Healthcare |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 0 | 1 | 2004 |
| ViiV Healthcare | For profit | 2 | 2 | 1 | 2004 |
2 organizations
Page 1 / 1